[{"path":"/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"GNU General Public License","title":"GNU General Public License","text":"Version 2, June 1991Copyright © 1989, 1991 Free Software Foundation, Inc.,51 Franklin Street, Fifth Floor, Boston, MA 02110-1301 USA Everyone permitted copy distribute verbatim copies license document, changing allowed.","code":""},{"path":"/LICENSE.html","id":"preamble","dir":"","previous_headings":"","what":"Preamble","title":"GNU General Public License","text":"licenses software designed take away freedom share change . contrast, GNU General Public License intended guarantee freedom share change free software–make sure software free users. General Public License applies Free Software Foundation’s software program whose authors commit using . (Free Software Foundation software covered GNU Lesser General Public License instead.) can apply programs, . speak free software, referring freedom, price. General Public Licenses designed make sure freedom distribute copies free software (charge service wish), receive source code can get want , can change software use pieces new free programs; know can things. protect rights, need make restrictions forbid anyone deny rights ask surrender rights. restrictions translate certain responsibilities distribute copies software, modify . example, distribute copies program, whether gratis fee, must give recipients rights . must make sure , , receive can get source code. must show terms know rights. protect rights two steps: (1) copyright software, (2) offer license gives legal permission copy, distribute /modify software. Also, author’s protection , want make certain everyone understands warranty free software. software modified someone else passed , want recipients know original, problems introduced others reflect original authors’ reputations. Finally, free program threatened constantly software patents. wish avoid danger redistributors free program individually obtain patent licenses, effect making program proprietary. prevent , made clear patent must licensed everyone’s free use licensed . precise terms conditions copying, distribution modification follow.","code":""},{"path":"/LICENSE.html","id":"terms-and-conditions-for-copying-distribution-and-modification","dir":"","previous_headings":"","what":"TERMS AND CONDITIONS FOR COPYING, DISTRIBUTION AND MODIFICATION","title":"GNU General Public License","text":"0. License applies program work contains notice placed copyright holder saying may distributed terms General Public License. “Program”, , refers program work, “work based Program” means either Program derivative work copyright law: say, work containing Program portion , either verbatim modifications /translated another language. (Hereinafter, translation included without limitation term “modification”.) licensee addressed “”. Activities copying, distribution modification covered License; outside scope. act running Program restricted, output Program covered contents constitute work based Program (independent made running Program). Whether true depends Program . 1. may copy distribute verbatim copies Program’s source code receive , medium, provided conspicuously appropriately publish copy appropriate copyright notice disclaimer warranty; keep intact notices refer License absence warranty; give recipients Program copy License along Program. may charge fee physical act transferring copy, may option offer warranty protection exchange fee. 2. may modify copy copies Program portion , thus forming work based Program, copy distribute modifications work terms Section 1 , provided also meet conditions: ) must cause modified files carry prominent notices stating changed files date change. b) must cause work distribute publish, whole part contains derived Program part thereof, licensed whole charge third parties terms License. c) modified program normally reads commands interactively run, must cause , started running interactive use ordinary way, print display announcement including appropriate copyright notice notice warranty (else, saying provide warranty) users may redistribute program conditions, telling user view copy License. (Exception: Program interactive normally print announcement, work based Program required print announcement.) requirements apply modified work whole. identifiable sections work derived Program, can reasonably considered independent separate works , License, terms, apply sections distribute separate works. distribute sections part whole work based Program, distribution whole must terms License, whose permissions licensees extend entire whole, thus every part regardless wrote . Thus, intent section claim rights contest rights work written entirely ; rather, intent exercise right control distribution derivative collective works based Program. addition, mere aggregation another work based Program Program (work based Program) volume storage distribution medium bring work scope License. 3. may copy distribute Program (work based , Section 2) object code executable form terms Sections 1 2 provided also one following: ) Accompany complete corresponding machine-readable source code, must distributed terms Sections 1 2 medium customarily used software interchange; , b) Accompany written offer, valid least three years, give third party, charge cost physically performing source distribution, complete machine-readable copy corresponding source code, distributed terms Sections 1 2 medium customarily used software interchange; , c) Accompany information received offer distribute corresponding source code. (alternative allowed noncommercial distribution received program object code executable form offer, accord Subsection b .) source code work means preferred form work making modifications . executable work, complete source code means source code modules contains, plus associated interface definition files, plus scripts used control compilation installation executable. However, special exception, source code distributed need include anything normally distributed (either source binary form) major components (compiler, kernel, ) operating system executable runs, unless component accompanies executable. distribution executable object code made offering access copy designated place, offering equivalent access copy source code place counts distribution source code, even though third parties compelled copy source along object code. 4. may copy, modify, sublicense, distribute Program except expressly provided License. attempt otherwise copy, modify, sublicense distribute Program void, automatically terminate rights License. However, parties received copies, rights, License licenses terminated long parties remain full compliance. 5. required accept License, since signed . However, nothing else grants permission modify distribute Program derivative works. actions prohibited law accept License. Therefore, modifying distributing Program (work based Program), indicate acceptance License , terms conditions copying, distributing modifying Program works based . 6. time redistribute Program (work based Program), recipient automatically receives license original licensor copy, distribute modify Program subject terms conditions. may impose restrictions recipients’ exercise rights granted herein. responsible enforcing compliance third parties License. 7. , consequence court judgment allegation patent infringement reason (limited patent issues), conditions imposed (whether court order, agreement otherwise) contradict conditions License, excuse conditions License. distribute satisfy simultaneously obligations License pertinent obligations, consequence may distribute Program . example, patent license permit royalty-free redistribution Program receive copies directly indirectly , way satisfy License refrain entirely distribution Program. portion section held invalid unenforceable particular circumstance, balance section intended apply section whole intended apply circumstances. purpose section induce infringe patents property right claims contest validity claims; section sole purpose protecting integrity free software distribution system, implemented public license practices. Many people made generous contributions wide range software distributed system reliance consistent application system; author/donor decide willing distribute software system licensee impose choice. section intended make thoroughly clear believed consequence rest License. 8. distribution /use Program restricted certain countries either patents copyrighted interfaces, original copyright holder places Program License may add explicit geographical distribution limitation excluding countries, distribution permitted among countries thus excluded. case, License incorporates limitation written body License. 9. Free Software Foundation may publish revised /new versions General Public License time time. new versions similar spirit present version, may differ detail address new problems concerns. version given distinguishing version number. Program specifies version number License applies “later version”, option following terms conditions either version later version published Free Software Foundation. Program specify version number License, may choose version ever published Free Software Foundation. 10. wish incorporate parts Program free programs whose distribution conditions different, write author ask permission. software copyrighted Free Software Foundation, write Free Software Foundation; sometimes make exceptions . decision guided two goals preserving free status derivatives free software promoting sharing reuse software generally.","code":""},{"path":"/LICENSE.html","id":"no-warranty","dir":"","previous_headings":"","what":"NO WARRANTY","title":"GNU General Public License","text":"11. PROGRAM LICENSED FREE CHARGE, WARRANTY PROGRAM, EXTENT PERMITTED APPLICABLE LAW. EXCEPT OTHERWISE STATED WRITING COPYRIGHT HOLDERS /PARTIES PROVIDE PROGRAM “” WITHOUT WARRANTY KIND, EITHER EXPRESSED IMPLIED, INCLUDING, LIMITED , IMPLIED WARRANTIES MERCHANTABILITY FITNESS PARTICULAR PURPOSE. ENTIRE RISK QUALITY PERFORMANCE PROGRAM . PROGRAM PROVE DEFECTIVE, ASSUME COST NECESSARY SERVICING, REPAIR CORRECTION. 12. EVENT UNLESS REQUIRED APPLICABLE LAW AGREED WRITING COPYRIGHT HOLDER, PARTY MAY MODIFY /REDISTRIBUTE PROGRAM PERMITTED , LIABLE DAMAGES, INCLUDING GENERAL, SPECIAL, INCIDENTAL CONSEQUENTIAL DAMAGES ARISING USE INABILITY USE PROGRAM (INCLUDING LIMITED LOSS DATA DATA RENDERED INACCURATE LOSSES SUSTAINED THIRD PARTIES FAILURE PROGRAM OPERATE PROGRAMS), EVEN HOLDER PARTY ADVISED POSSIBILITY DAMAGES. END TERMS CONDITIONS","code":""},{"path":"/LICENSE.html","id":"how-to-apply-these-terms-to-your-new-programs","dir":"","previous_headings":"","what":"How to Apply These Terms to Your New Programs","title":"GNU General Public License","text":"develop new program, want greatest possible use public, best way achieve make free software everyone can redistribute change terms. , attach following notices program. safest attach start source file effectively convey exclusion warranty; file least “copyright” line pointer full notice found. Also add information contact electronic paper mail. program interactive, make output short notice like starts interactive mode: hypothetical commands show w show c show appropriate parts General Public License. course, commands use may called something show w show c; even mouse-clicks menu items–whatever suits program. also get employer (work programmer) school, , sign “copyright disclaimer” program, necessary. sample; alter names: General Public License permit incorporating program proprietary programs. program subroutine library, may consider useful permit linking proprietary applications library. want , use GNU Lesser General Public License instead License.","code":"<one line to give the program's name and a brief idea of what it does.> Copyright (C) <year>  <name of author>  This program is free software; you can redistribute it and/or modify it under the terms of the GNU General Public License as published by the Free Software Foundation; either version 2 of the License, or (at your option) any later version.  This program is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the GNU General Public License for more details.  You should have received a copy of the GNU General Public License along with this program; if not, write to the Free Software Foundation, Inc., 51 Franklin Street, Fifth Floor, Boston, MA 02110-1301 USA. Gnomovision version 69, Copyright (C) year name of author Gnomovision comes with ABSOLUTELY NO WARRANTY; for details type `show w'. This is free software, and you are welcome to redistribute it under certain conditions; type `show c' for details. Yoyodyne, Inc., hereby disclaims all copyright interest in the program `Gnomovision' (which makes passes at compilers) written by James Hacker.  <signature of Ty Coon>, 1 April 1989 Ty Coon, President of Vice"},{"path":"/articles/abstract.html","id":"background-and-motivation","dir":"Articles","previous_headings":"","what":"Background and Motivation","title":"Project Abstract","text":"Colorectal cancer (CRC) third common cancer type second leading cause cancer deaths, representing 10% cancer diagnoses worldwide. United States, one million people living CRC, 4.2% percent adults expected diagnosed CRC point lives. CRC also highly metastatic–50% patients CRC expected experience metastases course disease.  recent decades, seen many advancements treatment metastatic CRC (mCRC), including developments traditional surgical /chemotherapy procedures (e.g. FOLFOX), new targeted therapies tailored individual genetic molecular profiles (e.g., Panitumumab, Aflibercept, etc.), well emergence new immunotherapeutic drugs (e.g., Pembrolizumab, Nivolumab, Ipilimumab). Knowing past trends clinical developments can provide valuable insights future directions mCRC treatment. Therefore, utilizing openly accessible database ClinicalTrials.gov, project aims explore summarize key underlying trends characteristics recent clinical trials mCRC, including 1) evolution distribution intervention categories (e.g., drug, device, behavioral, etc.) time, 2) number different therapeutic approaches investigated time, 3) factors impacting trial completion success (e.g., study type, phase, sponsorship, etc.). Addressing questions help obtain clearer picture current landscape clinical research condition mCRC, potentially showing us future prospects toward expanded treatment options enhanced precision medicines mCRC.","code":""},{"path":"/articles/abstract.html","id":"research-question","dir":"Articles","previous_headings":"","what":"Research Question","title":"Project Abstract","text":"factor(s) shows significant influence enrollment numbers mCRC clinical trials? Prediction: phase trial, enrollment numbers, source class collectively influence study duration mCRC clinical trials? Classification: can predict overall completion status using set factors, including enrollment, study duration, phase, intervention type, source class?","code":""},{"path":[]},{"path":"/articles/abstract.html","id":"datasets-used-in-analysis","dir":"Articles","previous_headings":"Data Cleaning and Exploration","what":"Datasets Used in Analysis","title":"Project Abstract","text":"first extract nct_ids clinical trials metastatic colorectal cancer clinicaltrials.gov database using dplyr filter query. , nct_ids used join datasets study information intervention types descriptions. allows us derive two datasets use analyses: crc data table contains information individual mCRC clinical trials, entry representing one trial. 717 entries 12 variables. Variables include study id, title, start date, completion date, phase, etc. crc_sub data table merged additional information intervention groups (arms) crc data table, one clinical trial potentially multiple groups. 1,697 entries 16 variables.","code":"library(bis620.final) crc |> head(5) #> # A tibble: 5 × 12 #>   nct_id      condition_name   start_date completion_date study_type brief_title #>   <chr>       <chr>            <date>     <date>          <chr>      <chr>       #> 1 NCT01531595 Metastatic Colo… 2012-02-29 2025-12-31      Intervent… Study of B… #> 2 NCT01531621 Metastatic Colo… 2012-02-29 2025-12-31      Observati… A Populati… #> 3 NCT01532804 Metastatic Colo… 2011-07-28 2019-01-31      Intervent… 2nd-line T… #> 4 NCT01533740 Metastatic Colo… 2012-03-31 2014-02-28      Observati… Circulatin… #> 5 NCT01539824 Metastatic Colo… 2012-02-29 2014-08-31      Intervent… A Study of… #> # ℹ 6 more variables: official_title <chr>, overall_status <chr>, phase <chr>, #> #   enrollment <dbl>, why_stopped <chr>, source_class <chr> crc_sub |> head(5) #> # A tibble: 5 × 16 #>   nct_id      condition_name intervention_id intervention_type intervention_name #>   <chr>       <chr>                    <dbl> <chr>             <chr>             #> 1 NCT01531595 Metastatic Co…        60057945 Drug              Bevacizumab plus… #> 2 NCT01531621 Metastatic Co…        60057946 Other             Biomarker sampli… #> 3 NCT01532804 Metastatic Co…        60058040 Drug              bevacizumab, oxa… #> 4 NCT01532804 Metastatic Co…        60058041 Drug              Bevacizumab, oxa… #> 5 NCT01533740 Metastatic Co…        60058119 Drug              fluorouracil/iri… #> # ℹ 11 more variables: description <chr>, start_date <date>, #> #   completion_date <date>, study_type <chr>, brief_title <chr>, #> #   official_title <chr>, overall_status <chr>, phase <chr>, enrollment <dbl>, #> #   why_stopped <chr>, source_class <chr>"},{"path":[]},{"path":"/articles/abstract.html","id":"eplorative-data-analysis","dir":"Articles","previous_headings":"Data Cleaning and Exploration > Data Visualization","what":"Eplorative Data Analysis","title":"Project Abstract","text":"understand underlying characteristics mCRC clinical trials, drew attention distribution interventional observational study designs, specifically stratified types intervention study phases. table shows clear dominance interventional (experimental) observational studies, well prominence interventions involving drugs forms. surprising drugs encompass wide range therapeutic approaches protein binding pathway-targeted drugs, immune checkpoint targeted drugs, chemotherapy drugs, prodominant treatment options. Finally, see clinical trials (interventional studies) phase 2 studies, defined “conducted evaluate effectiveness drug particular indication indications … determine common short-term side effects risks”. Showing Sankey diagram demonstrating information table. Yet included graph show straightforwardly proportionality distributions.","code":"summarize_crc_table() library(dplyr) #>  #> Attaching package: 'dplyr' #> The following objects are masked from 'package:stats': #>  #>     filter, lag #> The following objects are masked from 'package:base': #>  #>     intersect, setdiff, setequal, union library(ggalluvial) #> Loading required package: ggplot2 plot_crc_sankey(c('2000-01-01','2024-12-31'))"},{"path":"/articles/abstract.html","id":"visualization-evolution-over-time","dir":"Articles","previous_headings":"Data Cleaning and Exploration > Data Visualization","what":"Visualization: Evolution Over Time","title":"Project Abstract","text":"key question data evolving trend clinical trials time. therefore wanted visualize changes total number mCRC clinical trials 2000s 2020s. shows total number type interventions across time, can see 1) clear increase overall total number trials 2) proportions types interventions drugs seem also increase time.  investigate whether second observation actually true, generate another plot showing proportions different intervention types (shown ). may see slight increase proportion biological interventions time, types (procedure, radiation, etc.) remain generally unchanged. might suggest , traditional, gold-standard treatment, radiological surgical procedures actively research clinical trials; contrast, new drugs representing various therapeutic approaches constantly investigated clinical studies.  Lastly, make specific inquiries temporal trends clinical trials, wrote function allows querying data respect specific therapies, intervention types, given keywords plotting time trend accordingly. Bellow example one graphs showing number clinical trials intervention type “drug” time.","code":"plot_intervention_count_time() plot_intervention_proportion_time() plot_query_time_trend(\"drug\", quo(intervention_type))"},{"path":[]},{"path":"/articles/abstract.html","id":"anova","dir":"Articles","previous_headings":"Analysis","what":"Anova","title":"Project Abstract","text":"conducted statistical examinations assess variation enrollment numbers across 3 different factors: phase trial, duration study, source class.","code":""},{"path":"/articles/abstract.html","id":"enrollment-phase","dir":"Articles","previous_headings":"Analysis > Anova","what":"1. Enrollment ~ Phase","title":"Project Abstract","text":"ANOVA identify significant differences enrollment among trial phases, followed Tukey’s Honest Significant Difference (HSD) test conduct pairwise comparisons trial phases identify differences lay. Data visualized using box plots, highlighting enrollment distribution across phases. Outliers indicated red asterisks, representing enrollments notably higher lower typical range respective phases.","code":"enrollment_source_analysis() #>                Df   Sum Sq Mean Sq F value Pr(>F)     #> source_class    4  5313780 1328445    23.5 <2e-16 *** #> Residuals    1692 95664266   56539                    #> --- #> Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 #>  #>  Kruskal-Wallis rank sum test #>  #> data:  enrollment by source_class #> Kruskal-Wallis chi-squared = 103.3, df = 4, p-value < 2.2e-16"},{"path":"/articles/abstract.html","id":"enrollment-source-class","dir":"Articles","previous_headings":"Analysis > Anova","what":"2. Enrollment ~ Source Class","title":"Project Abstract","text":"performed ANOVA Kruskal-Wallis test determine significant differences enrollment among various source classes. visualize enrollment distributions, created histogram provided overview enrollment frequencies, bar plot depicted mean enrollment counts source class.","code":"enrollment_phase_analysis() #>               Df   Sum Sq Mean Sq F value Pr(>F)     #> phase          7 32213310 4601901   203.4 <2e-16 *** #> Residuals   1589 35944031   22621                    #> --- #> Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1"},{"path":"/articles/abstract.html","id":"enrollment-study-duration","dir":"Articles","previous_headings":"Analysis > Anova","what":"3. Enrollment ~ Study Duration","title":"Project Abstract","text":"Using ANOVA, assessed impact study duration enrollment numbers. Additionally, visualized relationship scatter plot created ggplot2, highlighted enrollment trends duration studies. data filtered include trials complete enrollment duration information, ensuring accuracy relevance analysis.","code":"enrollment_duration_analysis() #>               Df   Sum Sq Mean Sq F value Pr(>F)     #> study_time     1  5943390 5943390   110.1 <2e-16 *** #> Residuals   1674 90388794   53996                    #> --- #> Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1"},{"path":"/articles/abstract.html","id":"regression-analysis","dir":"Articles","previous_headings":"Analysis > Anova","what":"Regression Analysis:","title":"Project Abstract","text":"regression analysis performed fit predict study duration using several factors including enrollment, source class, phase.Key steps included filtering data completeness, transforming dates, calculating study duration. linear regression model fitted, outlier removal guided Cook’s distance threshold 4/n. refined model’s results evaluated diagnostic plots comparison Actual vs. Predicted study durations plot.","code":"duration_regression_analysis()"},{"path":"/articles/abstract.html","id":"overall-status-classification","dir":"Articles","previous_headings":"Analysis > Anova","what":"Overall Status Classification","title":"Project Abstract","text":"classification task, used set variables, including duration, enrollment, intervention_type, source_class, phase predict overall status clinical trial logistic regression model. Multiple combinations variables experimented optimize model performance. target variable overall_status converted binary variable classification task. Specifically, values “Recruiting”, “Completed”, “Active, recruiting”, “yet recruiting” defined class 1, values “Terminated”, “Withdrawn”, “Suspended” defined class 0. values “Unknown status” deleted included classification task. terms determining optimal probability threshold converting probabilities classes prediction, used pROC package helps determine optimal threshold.","code":"status_classification() #> Setting levels: control = 0, case = 1 #> Setting direction: controls < cases #>              #> pred_results   0   1 #>            0  63  66 #>            1  16 287 #> [1] \"Accuracy of Logistic Regression Model: 0.810185185185185\""},{"path":"/articles/abstract.html","id":"interpretation-and-conclusions","dir":"Articles","previous_headings":"","what":"Interpretation and Conclusions","title":"Project Abstract","text":"determine significant factors influencing enrollment numbers mCRC clinical trials, ANOVA tests conducted. three ANOVA summary tables indicate highly significant differences enrollment numbers across different phases clinical trials, source classes, study duration, evidenced low p-value (<0.05). Tukey’s HSD plot presents confidence intervals pairwise differences phases. plot shows several intervals (phase 3, phase 4, etc.) include zero, indicating significant differences mean enrollment certain phases. Kruskal-Wallis rank sum test result indicates highly significant difference enrollment numbers across various source classes clinical trials (chi-squared = 103.3). suggests source class likely influential factor affecting enrollment trials. predict collective influence different factors study duration mCRC clinical trials, multivariate linear regression model developed. regression output diagnostic plots provide insight relationship study duration predictors. output shows enrollment, NIH (source class), trial phase significant effects study duration. instance, funded NIH associated increase study duration, indicated large positive coefficient statistically significant. diagnostic plots suggest residuals reasonably well-behaved, obvious patterns Residuals vs Fitted plot. Scale-Location plot indicates variance residuals relatively constant across range fitted values. Though Residuals vs Leverage plot identifies potential outliers, acceptable Cook’s distance points common threshold. scatter plot Predicted vs Actual values shows well model’s predictions match actual data, points color-coded source class. Points falling along dashed line represent accurate predictions. dispersion points around line reflects variability prediction accuracy, potentially due unaccounted factors affecting study duration. observed points cluster (stratified) source class, revealing NIH-sourced trials generally exhibit shorter study durations, suggesting source-specific influences trial length. order classify overall completion status using different factors, built binary logistic regression model 81.0% accuracy. high level accuracy evidenced confusion matrix. model correctly predicted 63 trials meeting success criteria (true negatives) 287 meeting (true positives), misclassifying 16 false negatives 66 false positives. confusion matrix plot visually confirms model’s effectiveness, clear distinction successful unsuccessful trial classifications.","code":""},{"path":"/articles/abstract.html","id":"discussion","dir":"Articles","previous_headings":"","what":"Discussion","title":"Project Abstract","text":"Potential future directions study include carrying time series analyses distribution study phases change time, factors enrollment number, treatment approach, sponsorship come play. Moreover, take step , may conduct meta-analyses treatment efficacies outcome data available. example, can perform survival analyses (e.g., Kaplan-Meier curves, log-rank tests) compare effectiveness different therapeutic drugs. also noticed large proportion studies terminated suspended. information availabe database tell us exact reasons termination, might important investigate factors correlated trial success trial phase, targeted therapy types, etc.","code":""},{"path":"/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"package maintainer. Maintainer.","code":""},{"path":"/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Chen Y, Deng Y, Ji Z (2023). bis620.final: bis620.final. R package version 0.1.0, https://zqji0610.github.io/bis620.final/.","code":"@Manual{,   title = {bis620.final: bis620.final},   author = {Yining Chen and Yufei Deng and Ziqing Ji},   year = {2023},   note = {R package version 0.1.0},   url = {https://zqji0610.github.io/bis620.final/}, }"},{"path":"/index.html","id":"bis620final","dir":"","previous_headings":"","what":"bis620.final","title":"bis620.final","text":"bis620.final project aims explore current landscape clinical studies metastatic colorectal cancer (mCRC) using clinical trials metadata clinicaltrials.gov. package offers --shelf data visualization statistical analyses tools allows users understand characteristics recent mCRC clinical trials.","code":""},{"path":"/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"bis620.final","text":"can install development version bis620.final GitHub :","code":"install.packages(\"devtools\") install_github(\"zqji0610/bis620.final\")  # Or alternatively: devtools::install_github(\"zqji0610/bis620.final\")"},{"path":[]},{"path":"/index.html","id":"dataset","dir":"","previous_headings":"Example","what":"Dataset","title":"bis620.final","text":"code block shows one datasets using consists information 717 clinical trials related mCRC: Next, shows second dataset contains information specific interventions used clinical trials:","code":"library(bis620.final) crc |> head(5)  #> # A tibble: 5 × 12 #>   nct_id      condition_name   start_date completion_date study_type brief_title #>   <chr>       <chr>            <date>     <date>          <chr>      <chr>       #> 1 NCT01531595 Metastatic Colo… 2012-02-29 2025-12-31      Intervent… Study of B… #> 2 NCT01531621 Metastatic Colo… 2012-02-29 2025-12-31      Observati… A Populati… #> 3 NCT01532804 Metastatic Colo… 2011-07-28 2019-01-31      Intervent… 2nd-line T… #> 4 NCT01533740 Metastatic Colo… 2012-03-31 2014-02-28      Observati… Circulatin… #> 5 NCT01539824 Metastatic Colo… 2012-02-29 2014-08-31      Intervent… A Study of… #> # ℹ 6 more variables: official_title <chr>, overall_status <chr>, phase <chr>, #> #   enrollment <dbl>, why_stopped <chr>, source_class <chr> crc_sub |> head(5) #> # A tibble: 5 × 16 #>   nct_id      condition_name intervention_id intervention_type intervention_name #>   <chr>       <chr>                    <dbl> <chr>             <chr>             #> 1 NCT01531595 Metastatic Co…        60057945 Drug              Bevacizumab plus… #> 2 NCT01531621 Metastatic Co…        60057946 Other             Biomarker sampli… #> 3 NCT01532804 Metastatic Co…        60058040 Drug              bevacizumab, oxa… #> 4 NCT01532804 Metastatic Co…        60058041 Drug              Bevacizumab, oxa… #> 5 NCT01533740 Metastatic Co…        60058119 Drug              fluorouracil/iri… #> # ℹ 11 more variables: description <chr>, start_date <date>, #> #   completion_date <date>, study_type <chr>, brief_title <chr>, #> #   official_title <chr>, overall_status <chr>, phase <chr>, enrollment <dbl>, #> #   why_stopped <chr>, source_class <chr>"},{"path":"/index.html","id":"data-visualization--analyses","dir":"","previous_headings":"Example","what":"Data Visualization & Analyses","title":"bis620.final","text":"snapshots implementing functions package:","code":"summarize_crc_table() plot_crc_sankey() plot_intervention_count_time()"},{"path":"/index.html","id":"statistical-analyses","dir":"","previous_headings":"Example","what":"Statistical Analyses","title":"bis620.final","text":"","code":"enrollment_source_analysis() enrollment_phase_analysis() enrollment_duration_analysis()"},{"path":"/index.html","id":"regression-of-duration","dir":"","previous_headings":"Example","what":"Regression of Duration","title":"bis620.final","text":"","code":"duration_regression_analysis()"},{"path":"/index.html","id":"classification-of-overall-status","dir":"","previous_headings":"Example","what":"Classification of Overall Status","title":"bis620.final","text":"","code":"status_classification()"},{"path":"/reference/crc.html","id":null,"dir":"Reference","previous_headings":"","what":"Data for Metastatic Colorectal Cancer clinical trials — crc","title":"Data for Metastatic Colorectal Cancer clinical trials — crc","text":"Data Metastatic Colorectal Cancer clinical trials","code":""},{"path":"/reference/crc.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Data for Metastatic Colorectal Cancer clinical trials — crc","text":"","code":"crc"},{"path":[]},{"path":"/reference/crc.html","id":"crc","dir":"Reference","previous_headings":"","what":"crc","title":"Data for Metastatic Colorectal Cancer clinical trials — crc","text":"data frame 717 rows 12 columns: nct_id identifier clinical trials. tudy_type interventional observations. brief_title brief description clinical trial. phase study phase.","code":""},{"path":"/reference/crc_sub.html","id":null,"dir":"Reference","previous_headings":"","what":"Data for Metastatic Colorectal Cancer clinical trials with specific interventions — crc_sub","title":"Data for Metastatic Colorectal Cancer clinical trials with specific interventions — crc_sub","text":"Data Metastatic Colorectal Cancer clinical trials specific interventions","code":""},{"path":"/reference/crc_sub.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Data for Metastatic Colorectal Cancer clinical trials with specific interventions — crc_sub","text":"","code":"crc_sub"},{"path":[]},{"path":"/reference/crc_sub.html","id":"crc-sub","dir":"Reference","previous_headings":"","what":"crc_sub","title":"Data for Metastatic Colorectal Cancer clinical trials with specific interventions — crc_sub","text":"data frame 1697 rows 16 columns: nct_id identifier clinical trials. intervention_type specific types interventions (e.g., Drug, Procedure, Biological, etc.).","code":""},{"path":"/reference/duration_regression_analysis.html","id":null,"dir":"Reference","previous_headings":"","what":"Regression Analysis of Study Duration — duration_regression_analysis","title":"Regression Analysis of Study Duration — duration_regression_analysis","text":"function performs regression analysis duration studies, considering factors enrollment, source class, phase. analysis includes removal outliers based Cook's distance, conducted within specified date range.","code":""},{"path":"/reference/duration_regression_analysis.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Regression Analysis of Study Duration — duration_regression_analysis","text":"","code":"duration_regression_analysis(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/duration_regression_analysis.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Regression Analysis of Study Duration — duration_regression_analysis","text":"dates list two date values (start end date, respectively) define period analysis.","code":""},{"path":"/reference/duration_regression_analysis.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Regression Analysis of Study Duration — duration_regression_analysis","text":"function returns results regression analysis, diagnostic plots assess model, plot comparing actual vs predicted values study duration.","code":""},{"path":"/reference/enrollment_duration_analysis.html","id":null,"dir":"Reference","previous_headings":"","what":"Statistical Analysis of Enrollment Across Trials with Duration of Study — enrollment_duration_analysis","title":"Statistical Analysis of Enrollment Across Trials with Duration of Study — enrollment_duration_analysis","text":"function performs statistical analysis explore relationship enrollment counts study duration colorectal cancer trials within specified date range. analysis includes ANOVA creation scatter plot visualizing relationship.","code":""},{"path":"/reference/enrollment_duration_analysis.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Statistical Analysis of Enrollment Across Trials with Duration of Study — enrollment_duration_analysis","text":"","code":"enrollment_duration_analysis(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/enrollment_duration_analysis.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Statistical Analysis of Enrollment Across Trials with Duration of Study — enrollment_duration_analysis","text":"dates list two date values (lower upper, respectively) defining period analysis.","code":""},{"path":"/reference/enrollment_duration_analysis.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Statistical Analysis of Enrollment Across Trials with Duration of Study — enrollment_duration_analysis","text":"Returns results ANOVA analysis scatter plot showing relationship study duration enrollment counts.","code":""},{"path":"/reference/enrollment_phase_analysis.html","id":null,"dir":"Reference","previous_headings":"","what":"Statistical analysis of enrollment across trials with different phases — enrollment_phase_analysis","title":"Statistical analysis of enrollment across trials with different phases — enrollment_phase_analysis","text":"Given specific date range, functions explores differences enrollment counts across different colorectal cancer trials different phases, performing ANOVA Tukey's Honest Significant Difference (HSD) test generating associated visualizations.","code":""},{"path":"/reference/enrollment_phase_analysis.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Statistical analysis of enrollment across trials with different phases — enrollment_phase_analysis","text":"","code":"enrollment_phase_analysis(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/enrollment_phase_analysis.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Statistical analysis of enrollment across trials with different phases — enrollment_phase_analysis","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/enrollment_phase_analysis.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Statistical analysis of enrollment across trials with different phases — enrollment_phase_analysis","text":"Results ANOVA Tukey's HSD test, box plot showing enrollment distribution phases, 95% Family-Wise Confidence Level Plot.","code":""},{"path":"/reference/enrollment_source_analysis.html","id":null,"dir":"Reference","previous_headings":"","what":"Statistical analysis of enrollment across trials with different source classes — enrollment_source_analysis","title":"Statistical analysis of enrollment across trials with different source classes — enrollment_source_analysis","text":"Given specific date range, functions explores differences enrollment counts across different colorectal cancer trials different source classes, performing ANOVA Kruskal-Wallis generating associated visualizations.","code":""},{"path":"/reference/enrollment_source_analysis.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Statistical analysis of enrollment across trials with different source classes — enrollment_source_analysis","text":"","code":"enrollment_source_analysis(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/enrollment_source_analysis.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Statistical analysis of enrollment across trials with different source classes — enrollment_source_analysis","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/enrollment_source_analysis.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Statistical analysis of enrollment across trials with different source classes — enrollment_source_analysis","text":"Results ANOVA Kruskal-Wallis test, enrollment distribution histogram, barp lot showing mean enrollment counts across different source classes","code":""},{"path":"/reference/plot_crc_sankey.html","id":null,"dir":"Reference","previous_headings":"","what":"Sankey plot of trial study types, intervention types, and phases — plot_crc_sankey","title":"Sankey plot of trial study types, intervention types, and phases — plot_crc_sankey","text":"Filters mCRC clinical trials within given range trial start date visualizes Sankey diagram showing distribution study types stratified intervention types phases","code":""},{"path":"/reference/plot_crc_sankey.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Sankey plot of trial study types, intervention types, and phases — plot_crc_sankey","text":"","code":"plot_crc_sankey(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/plot_crc_sankey.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Sankey plot of trial study types, intervention types, and phases — plot_crc_sankey","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/plot_crc_sankey.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Sankey plot of trial study types, intervention types, and phases — plot_crc_sankey","text":"Sankey (Alluvial) plot showing clinical trials distribution","code":""},{"path":"/reference/plot_intervention_count_time.html","id":null,"dir":"Reference","previous_headings":"","what":"Histogram of different intervention types over time — plot_intervention_count_time","title":"Histogram of different intervention types over time — plot_intervention_count_time","text":"Filters mCRC clinical trials within given range trial start date plots histogram showing number intervention type time","code":""},{"path":"/reference/plot_intervention_count_time.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Histogram of different intervention types over time — plot_intervention_count_time","text":"","code":"plot_intervention_count_time(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/plot_intervention_count_time.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Histogram of different intervention types over time — plot_intervention_count_time","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/plot_intervention_count_time.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Histogram of different intervention types over time — plot_intervention_count_time","text":"histogram showing number intervention types vs. time","code":""},{"path":"/reference/plot_intervention_proportion_time.html","id":null,"dir":"Reference","previous_headings":"","what":"Proportions of differnt intervention types over time — plot_intervention_proportion_time","title":"Proportions of differnt intervention types over time — plot_intervention_proportion_time","text":"Filters mCRC clinical trials within given range trial start date plots density plot showing proportion intervention type time","code":""},{"path":"/reference/plot_intervention_proportion_time.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Proportions of differnt intervention types over time — plot_intervention_proportion_time","text":"","code":"plot_intervention_proportion_time(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/plot_intervention_proportion_time.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Proportions of differnt intervention types over time — plot_intervention_proportion_time","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/plot_intervention_proportion_time.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Proportions of differnt intervention types over time — plot_intervention_proportion_time","text":"density plot showing proportion intervention types vs. time","code":""},{"path":"/reference/plot_query_time_trend.html","id":null,"dir":"Reference","previous_headings":"","what":"Function that query the clinical trial table and plots the number of trials\nmatching the given keywords over time. — plot_query_time_trend","title":"Function that query the clinical trial table and plots the number of trials\nmatching the given keywords over time. — plot_query_time_trend","text":"Function query clinical trial table plots number trials matching given keywords time.","code":""},{"path":"/reference/plot_query_time_trend.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function that query the clinical trial table and plots the number of trials\nmatching the given keywords over time. — plot_query_time_trend","text":"","code":"plot_query_time_trend(kwds, column, ignore.case = TRUE, match_all = FALSE)"},{"path":"/reference/plot_query_time_trend.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function that query the clinical trial table and plots the number of trials\nmatching the given keywords over time. — plot_query_time_trend","text":"kwds string / list strings. query keyword(s) column quosure (string enclosed quo()). column filtered upon. ignore.case Boolean, default TRUE. Specify whether query case-insensitive match_all Boolean, default FALSE. Specify whether query requires column value match kwds just one ","code":""},{"path":"/reference/plot_query_time_trend.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Function that query the clinical trial table and plots the number of trials\nmatching the given keywords over time. — plot_query_time_trend","text":"line plot showing count queried clinical trials time","code":""},{"path":"/reference/query_kwds.html","id":null,"dir":"Reference","previous_headings":"","what":"Function that queries the crc_sub table using a keyword/a list of keyword strings — query_kwds","title":"Function that queries the crc_sub table using a keyword/a list of keyword strings — query_kwds","text":"Function queries crc_sub table using keyword/list keyword strings","code":""},{"path":"/reference/query_kwds.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function that queries the crc_sub table using a keyword/a list of keyword strings — query_kwds","text":"","code":"query_kwds(kwds, column, ignore.case = TRUE, match_all = FALSE)"},{"path":"/reference/query_kwds.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function that queries the crc_sub table using a keyword/a list of keyword strings — query_kwds","text":"kwds string / list strings. query keyword(s) column quosure (string enclosed quo()). column filtered upon. ignore.case Boolean, default TRUE. Specify whether query case-insensitive match_all Boolean, default FALSE. Specify whether query requires column value match kwds just one ","code":""},{"path":"/reference/query_kwds.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Function that queries the crc_sub table using a keyword/a list of keyword strings — query_kwds","text":"table filtered entries","code":""},{"path":"/reference/status_classification.html","id":null,"dir":"Reference","previous_headings":"","what":"Overall Status classification task — status_classification","title":"Overall Status classification task — status_classification","text":"Given specific date range, functions classifies overall status using set predictor values, including enrollment, duration, phase, intervention type source class logistic regression model","code":""},{"path":"/reference/status_classification.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Overall Status classification task — status_classification","text":"","code":"status_classification(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/status_classification.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Overall Status classification task — status_classification","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/status_classification.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Overall Status classification task — status_classification","text":"Results logistic regression model, including confusion matrix, accuracy levels, graph visualizing confusion matrix values.","code":""},{"path":"/reference/summarize_crc_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Summary table of clinical study types, intervention types, and phases — summarize_crc_table","title":"Summary table of clinical study types, intervention types, and phases — summarize_crc_table","text":"Filters mCRC clinical trials within given range trial start date creates summary table showing distribution study types stratified intervention types phases","code":""},{"path":"/reference/summarize_crc_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Summary table of clinical study types, intervention types, and phases — summarize_crc_table","text":"","code":"summarize_crc_table(dates = c(\"2000-01-01\", \"2100-01-01\"))"},{"path":"/reference/summarize_crc_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Summary table of clinical study types, intervention types, and phases — summarize_crc_table","text":"dates list two date values (lower upper, respectively)","code":""},{"path":"/reference/summarize_crc_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Summary table of clinical study types, intervention types, and phases — summarize_crc_table","text":"summary table showing clinical trials distribution","code":""}]
